These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 17315048)
41. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells. Okabe S; Tauchi T; Ohyashiki K Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496 [TBL] [Abstract][Full Text] [Related]
42. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Santos FP; Cortes J Expert Opin Pharmacother; 2012 Nov; 13(16):2381-95. PubMed ID: 22992064 [TBL] [Abstract][Full Text] [Related]
43. Hematology: dasatinib regimens for patients with chronic myeloid leukemia. Guilhot F; Roy L Nat Rev Clin Oncol; 2009 Dec; 6(12):680-2. PubMed ID: 19942922 [TBL] [Abstract][Full Text] [Related]
44. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071 [TBL] [Abstract][Full Text] [Related]
45. Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. McFarland KL; Wetzstein GA Cancer Control; 2009 Apr; 16(2):132-40. PubMed ID: 19337199 [TBL] [Abstract][Full Text] [Related]
46. Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. McCormack PL; Keam SJ BioDrugs; 2012 Feb; 26(1):61-4. PubMed ID: 22233429 [TBL] [Abstract][Full Text] [Related]
47. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Ottmann O; Dombret H; Martinelli G; Simonsson B; Guilhot F; Larson RA; Rege-Cambrin G; Radich J; Hochhaus A; Apanovitch AM; Gollerkeri A; Coutre S Blood; 2007 Oct; 110(7):2309-15. PubMed ID: 17496201 [TBL] [Abstract][Full Text] [Related]
48. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Klyuchnikov E; Schafhausen P; Kröger N; Brummendorf TH; Osanmaz O; Asenova S; Zabelina T; Ocheni S; Ayuk F; Zander AR; Bacher U Acta Haematol; 2009; 122(1):6-10. PubMed ID: 19602874 [No Abstract] [Full Text] [Related]
49. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Foà R; Vitale A; Vignetti M; Meloni G; Guarini A; De Propris MS; Elia L; Paoloni F; Fazi P; Cimino G; Nobile F; Ferrara F; Castagnola C; Sica S; Leoni P; Zuffa E; Fozza C; Luppi M; Candoni A; Iacobucci I; Soverini S; Mandelli F; Martinelli G; Baccarani M; Blood; 2011 Dec; 118(25):6521-8. PubMed ID: 21931113 [TBL] [Abstract][Full Text] [Related]
50. Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Sakamaki H; Ishizawa KI; Taniwaki M; Fujisawa S; Morishima Y; Tobinai K; Okada M; Ando K; Usui N; Miyawaki S; Utsunomiya A; Uoshima N; Nagai T; Naoe T; Motoji T; Jinnai I; Tanimoto M; Miyazaki Y; Ohnishi K; Iida S; Okamoto S; Seriu T; Ohno R Int J Hematol; 2009 Apr; 89(3):332-341. PubMed ID: 19263190 [TBL] [Abstract][Full Text] [Related]
51. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Porkka K; Koskenvesa P; Lundán T; Rimpiläinen J; Mustjoki S; Smykla R; Wild R; Luo R; Arnan M; Brethon B; Eccersley L; Hjorth-Hansen H; Höglund M; Klamova H; Knutsen H; Parikh S; Raffoux E; Gruber F; Brito-Babapulle F; Dombret H; Duarte RF; Elonen E; Paquette R; Zwaan CM; Lee FY Blood; 2008 Aug; 112(4):1005-12. PubMed ID: 18477770 [TBL] [Abstract][Full Text] [Related]
56. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. Ravandi F Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):198-203. PubMed ID: 21575924 [TBL] [Abstract][Full Text] [Related]
57. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Gardner LA; Klawitter J; Gregory MA; Zaberezhnyy V; Baturin D; Pollyea DA; Takebe N; Christians U; Gore L; DeGregori J; Porter CC Am J Hematol; 2014 Sep; 89(9):896-903. PubMed ID: 24891015 [TBL] [Abstract][Full Text] [Related]
58. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. De Melo VA; Milojkovic D; Khorashad JS; Marin D; Goldman JM; Apperley JF; Reid AG Blood; 2007 Oct; 110(8):3086-7. PubMed ID: 17916757 [No Abstract] [Full Text] [Related]
59. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia. Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798 [TBL] [Abstract][Full Text] [Related]
60. Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. Kim DW; Goh YT; Hsiao HH; Caguioa PB; Kim D; Kim WS; Saikia T; Agrawal S; Roy A; Dai D; Bradley-Garelik MB; Mukhopadhyay J; Jootar S Int J Hematol; 2009 Jun; 89(5):664-72. PubMed ID: 19455391 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]